Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Clomiphene citrate
Drug ID BADD_D00498
Description A triphenyl ethylene stilbene derivative which is an estrogen agonist or antagonist depending on the target tissue.
Indications and Usage Used mainly in female infertility due to anovulation (e.g. due to polycystic ovary syndrome) to induce ovulation.
Marketing Status approved; investigational
ATC Code G03GB02
DrugBank ID DB00882
KEGG ID D00962
MeSH ID D002996
PubChem ID 60974
TTD Drug ID D0I5WB
NDC Product Code 51927-0249; 73377-229; 49884-701; 50090-0678; 10577-916; 46014-1122; 51927-0056; 0713-0885; 73212-029; 63629-2165; 63629-5302; 63275-9964; 63629-9276; 48087-0025; 49169-1040; 51552-1580; 68071-2638; 73309-047; 50090-6500; 17369-817; 48087-0144; 62991-2702; 61919-375; 38779-0390; 43647-456; 71052-338; 90027-025
UNII 1B8447E7YI
Synonyms Clomiphene | Clomifene | Chloramiphene | Clomifen | Clomiphene Citrate | Citrate, Clomiphene | Clomiphene Hydrochloride | Hydrochloride, Clomiphene | Serophene | Gravosan | Klostilbegit | Clostilbegit | Clomid | Clomide | Dyneric
Chemical Information
Molecular Formula C32H36ClNO8
CAS Registry Number 50-41-9
SMILES CCN(CC)CCOC1=CC=C(C=C1)C(=C(C2=CC=CC=C2)Cl)C3=CC=CC=C3.C(C(=O)O)C(CC(=O)O)(C(=O) O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pruritus23.03.12.001--
Pulmonary embolism22.06.02.001; 24.01.06.001---
Pyrexia08.05.02.003--
Rash23.03.13.001---
Retinal haemorrhage06.10.01.001; 24.07.05.003---
Retinal vascular disorder06.10.01.002; 24.03.07.002--
Seizure17.12.03.001--
Syncope02.11.04.015; 17.02.04.008; 24.06.02.012--
Tachycardia02.03.02.007---
Tension19.06.02.005---
Thrombophlebitis24.01.02.001---
Thyroid disorder05.02.01.002---
Thyroid neoplasm05.02.05.002; 16.24.01.002---
Tinnitus04.04.01.002; 17.04.07.004--
Tongue neoplasm malignant stage unspecified07.21.07.003; 16.13.07.003---
Tracheo-oesophageal fistula03.16.02.002; 07.11.05.003; 22.04.07.003---
Trisomy 2102.08.02.003; 03.20.01.002; 17.03.07.005; 19.21.06.005---
Urticaria10.01.06.001; 23.04.02.001--
Uterine haemorrhage21.07.01.005; 24.07.03.004--
Vasoconstriction23.06.05.007; 24.04.03.008---
Ventricular septal defect02.04.02.007; 03.07.02.001---
Vertigo04.04.01.003; 17.02.12.002--
Vision blurred06.02.06.007; 17.17.01.010--
Visual acuity tests abnormal13.07.04.009---
Visual field defect06.02.07.003; 17.17.01.001---
Vitreous detachment06.09.01.002; 12.01.04.005---
Vitreous floaters06.09.01.005--
Vomiting07.01.07.003--
Vulvovaginal dryness21.08.02.003--
Weight decreased13.15.01.005--
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages